ADVFN Logo ADVFN

No pudimos encontrar ningún resultado para:
Asegúrate de que la ortografía sea correcta o intenta ampliar tu búsqueda.

Tendencias Ahora

Listas Principales

Parece que no has iniciado sesión.
Haz clic en el botón de abajo para iniciar sesión y ver tu historial reciente.

Regístrate

¿Ya eres miembro? Iniciar sesión

Los Principales Corredores en Línea

Más Corredores en Línea

Datos
Noticias
Herramientas
Mercados
Descubrir

Hot Features

Follow Feed

Conéctese con traders e inversores en nuestra comunidad Follow Feed.

Flujo de Opciones

Explora datos de opciones completos y utiliza filtros avanzados con Options Flow.

Monitor

Organiza y monitorea tu lista de seguimiento de acciones y activos con Monitor.
Iniciar Sesión Premium IconPremium Help Menu
S&P 500
5,304.72
0.70%
Dow Jones
39,069.59
0.01%
US Dollar vs MXN
16.6998
0.00%
Brent Oil
81.965
0.00%
Bitcoin
69,087.98
-0.26%
Registration Strip Icon for default Regístrate gratis para obtener cotizaciones en tiempo real, gráficos interactivos, flujo de opciones en vivo y más.
Regístrate
  1. Inicio
  2. Invertir
  3. Acciones
  4. Estados Unidos
  5. NASDAQ
  6. Panbela Therapeutics Inc (PBLA)

  7. Panbela Therapeutics Inc (PBLA) Noticias

PBLA

Panbela Therapeutics (PBLA)

Panbela Therapeutics Inc
Fecha:
Ordernar por:
 Showing the most relevant articles for your search:NASDAQ:PBLA
FechaHoraFuenteTítuloSímboloCompañía
15/05/202415:10GlobeNewswire Inc.Panbela Provides Business Update and Reports Q1 2024 Financial ResultsNASDAQ:PBLAPanbela Therapeutics Inc
06/05/202407:00GlobeNewswire Inc.Panbela Announces Issuance of New Patent in the US and Canada; Patent is for Claims of a Fixed Dose Combination of Eflornithine and SulindacNASDAQ:PBLAPanbela Therapeutics Inc
01/05/202415:15GlobeNewswire Inc.Panbela to Host First Quarter 2024 Earnings Conference Call on May 15, 2024NASDAQ:PBLAPanbela Therapeutics Inc
30/04/202407:00GlobeNewswire Inc.Acceptance of Eflornithine (DFMO) Abstract for Oral Presentation at Digestive Disease WeekNASDAQ:PBLAPanbela Therapeutics Inc
26/04/202415:39Edgar (US Regulatory)Form PRER14A - Preliminary Proxy Soliciting materialsNASDAQ:PBLAPanbela Therapeutics Inc
25/04/202415:36Edgar (US Regulatory)Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) materialNASDAQ:PBLAPanbela Therapeutics Inc
25/04/202415:35Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:PBLAPanbela Therapeutics Inc
25/04/202408:09Edgar (US Regulatory)Form 25-NSE - Notification filed by national security exchange to report the removal from listing and registration of matured, redeemed or retired securitiesNASDAQ:PBLAPanbela Therapeutics Inc
22/04/202407:00GlobeNewswire Inc.Panbela Therapeutics Announces Interim Data Analysis for ASPIRE Trial Pushed to Q1 2025NASDAQ:PBLAPanbela Therapeutics Inc
18/04/202415:31Edgar (US Regulatory)Form S-1 - General form for registration of securities under the Securities Act of 1933NASDAQ:PBLAPanbela Therapeutics Inc
18/04/202407:00GlobeNewswire Inc.Panbela Announces Poster Presentation at American Association for Cancer Research:NASDAQ:PBLAPanbela Therapeutics Inc
16/04/202423:15Edgar (US Regulatory)Form EFFECT - Notice of EffectivenessNASDAQ:PBLAPanbela Therapeutics Inc
16/04/202416:29GlobeNewswire Inc.Panbela Announces Transfer to OTCQB MarketNASDAQ:PBLAPanbela Therapeutics Inc
04/04/202415:17Edgar (US Regulatory)Form DEF 14A - Other definitive proxy statementsNASDAQ:PBLAPanbela Therapeutics Inc
29/03/202416:08Edgar (US Regulatory)Form POS AM - Post-Effective amendments for registration statementNASDAQ:PBLAPanbela Therapeutics Inc
26/03/202415:15Edgar (US Regulatory)Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]NASDAQ:PBLAPanbela Therapeutics Inc
26/03/202415:10GlobeNewswire Inc.Panbela Provides Business Update and Reports Q4 and FY 2024 Financial ResultsNASDAQ:PBLAPanbela Therapeutics Inc
26/03/202406:21IH Market NewsU.S. Index Futures on the Rise, Oil Prices Show StabilityNASDAQ:PBLAPanbela Therapeutics Inc
25/03/202415:15Edgar (US Regulatory)Form PRE 14A - Other preliminary proxy statementsNASDAQ:PBLAPanbela Therapeutics Inc
12/03/202415:15GlobeNewswire Inc.Panbela to Host Fourth Quarter and Year End 2023 Earnings Conference Call on March 26, 2024NASDAQ:PBLAPanbela Therapeutics Inc
15/02/202407:00GlobeNewswire Inc.Panbela Regains Compliance with Nasdaq Listing Standards for Bid Price and Publicly Held Shares RequirementsNASDAQ:PBLAPanbela Therapeutics Inc
13/02/202419:10Edgar (US Regulatory)Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]NASDAQ:PBLAPanbela Therapeutics Inc
01/02/202406:00GlobeNewswire Inc.Panbela Announces Closing of Approximately $9.0 Million Public OfferingNASDAQ:PBLAPanbela Therapeutics Inc
30/01/202416:28Edgar (US Regulatory)Form 424B4 - Prospectus [Rule 424(b)(4)]NASDAQ:PBLAPanbela Therapeutics Inc
30/01/202407:15GlobeNewswire Inc.Acceptance of Ivospemin (SBP-101) Abstract for Poster Presentation at American Association for Cancer Research (AACR)NASDAQ:PBLAPanbela Therapeutics Inc
29/01/202405:15GlobeNewswire Inc.Panbela Announces Pricing of Approximately $9.0 Million Public OfferingNASDAQ:PBLAPanbela Therapeutics Inc
25/01/202411:22Edgar (US Regulatory)Form S-1/A - General form for registration of securities under the Securities Act of 1933: [Amend]NASDAQ:PBLAPanbela Therapeutics Inc
25/01/202406:00GlobeNewswire Inc.Panbela Exceeds 50% Enrollment for Aspire Trial in Pancreatic Cancer, Exceeding Anticipated Timelines with Accelerated MomentumNASDAQ:PBLAPanbela Therapeutics Inc
18/01/202407:15GlobeNewswire Inc.Panbela Announces Publication of Clinical Data Titled: Phase 1 study of high-dose DFMO, celecoxib, cyclophosphamide and topotecan for patients with relapsed neuroblastoma: A New Approaches to Neuroblastoma Therapy TrialNASDAQ:PBLAPanbela Therapeutics Inc
16/01/202407:00GlobeNewswire Inc.Panbela Announces 1-for-20 Reverse Stock Split Effective January 18, 2024NASDAQ:PBLAPanbela Therapeutics Inc
 Showing the most relevant articles for your search:NASDAQ:PBLA

Su Consulta Reciente

COIN
QBICEUR
BIT
P1BRG0
BNP Paribas Issuance
BOV
PETR-DEB620B
PETROBRAS
NASDAQ
PCCTW
Perception Capital Corpo...
BIT
FLOWVO
Vontobel Financial Produ...
TSXV
FS
USOTC
BQMCY
Bank of Africa (PK)
NYSE
COLE
Cole Real Estate
BIT
UC611V
Unicredit Bank
BIBX
BNTDEUSDT
BNTDE
USOTC
BXRX
Baudax Bio (PK)
LSE
11BL
Bank Mont.43
BIT
1GD
General Dynamics
COIN
NANJGBP
NANJCOIN
ASX
ENN
Elanor Investors
NASDAQ
FLLCW
Fellazo
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

México
Empresa
Negocios
Popular
Obtener la aplicación
App Store
Google Play

Soporte: (55) 4170 8128 | soporte@advfn.mx

Al acceder a los servicios disponibles de ADVFN usted acepta quedar sujerto a los Términos y Condiciones

© 2024 ADVFN PLC - Todos los derechos reservados